{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:26Z","timestamp":1794047486742,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.286332","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T04:10:25Z","timestamp":1730347825000},"page":"791-794","source":"Crossref","is-referenced-by-count":2,"title":["Impact of daratumumab\/bortezomib\/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience"],"prefix":"10.3324","volume":"110","author":[{"given":"Marika","family":"Porrazzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Moscato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sapienza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Accardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Cangialosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Costanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Tringali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rotolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Gigliotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rizzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela Giuseppa","family":"Ingrasc\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Butera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Di Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Marfia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cirino","family":"Botta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"73535","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Terpos E. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(3):309-322.","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"73536","doi-asserted-by":"crossref","unstructured":"Giralt S, Costa L, Schriber J. Optimizing autologous stem cell mobilization strategies to improve patients outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014; 20(3):295-308.","DOI":"10.1016\/j.bbmt.2013.10.013"},{"key":"73537","doi-asserted-by":"crossref","unstructured":"Di Persio JF, Stadtmauer EA, Nademanee A. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009; 113(23):5720-5726.","DOI":"10.1182\/blood-2008-08-174946"},{"key":"73538","doi-asserted-by":"crossref","unstructured":"Venglar O, Kapustova V, Sithara AA. Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy. Br J Haematol. 2024; 204(4):1439-1449.","DOI":"10.1111\/bjh.19141"},{"key":"73539","doi-asserted-by":"crossref","unstructured":"Moreau P, Attal M, Hulin C. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10192):29-38.","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"73540","doi-asserted-by":"crossref","unstructured":"Voorhees PM, Kaufman JL, Laubach J. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020; 136(8):936-945.","DOI":"10.1182\/blood.2020005288"},{"key":"73541","doi-asserted-by":"crossref","unstructured":"Costa LJ, Chhabra S, Medvedova E. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022; 40(25):2901-2912.","DOI":"10.1200\/JCO.21.01935"},{"key":"73542","doi-asserted-by":"crossref","unstructured":"Thurlapati A, Roubal K, Davis JA. Stem cell mobilization for multiple myeloma patients receiving daratumumab-based induction therapy: a real-world experience. Transplant Cell Ther. 2023; 29(5):340.e1-340.e4.","DOI":"10.1016\/j.jtct.2023.02.013"},{"key":"73543","doi-asserted-by":"crossref","unstructured":"Sauer S, Kriegsmann K, Nientiedt C. Stem cell collection after daratumumab, bortezomib, thalidomide, and dexamethasone versus bortezomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma. Transfus Med Hemother. 2023; 50(5):371-380.","DOI":"10.1159\/000529691"},{"key":"73544","unstructured":"Zappaterra A, Civettini I, Cafro AM. Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients. Blood Transfus. 2024; 22(4):328-337."},{"key":"73545","doi-asserted-by":"crossref","unstructured":"Liberatore C, Perini T, Passeri C. Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma Haematologica. 2023; 108(12):3502-3505.","DOI":"10.3324\/haematol.2023.283452"},{"key":"73546","doi-asserted-by":"crossref","unstructured":"Papaiakovou EE, Terpos E, Kanellias N. Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation. Leuk Lymphoma. 2023; 64(13):2140-2147.","DOI":"10.1080\/10428194.2023.2253479"},{"key":"73547","doi-asserted-by":"crossref","unstructured":"Mina R, Petrucci MT, Bonello F. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and \u2018on-demand\u2019 plerixafor in multiple myeloma patients treated with novel agents. Haematologica. 2024; 109(5):1525-1534.","DOI":"10.3324\/haematol.2023.284023"},{"key":"73548","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A. International Myeloma Working Group updated criteria for diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-548.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"73549","doi-asserted-by":"crossref","unstructured":"Chhabra S, Callander N, Watts NL. Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials. Transplant Cell Ther. 2023; 29(3):174.e1-174.e10.","DOI":"10.1016\/j.jtct.2022.11.029"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286332\/77738","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286332\/78142","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11808\/77738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:32Z","timestamp":1794046052000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.286332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286332","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}